glp 1 china More Chinese biotechs challenge GLP-1 dominance in diabetes Ozempic craze hits China as

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

These findings align with prior randomized trials and meta-analyses suggesting class-level cardiovascular benefit

Gut health plus weight loss.

Get insights on navigating GLP-1 antagonist shortages and compounds as we navigate demand and supply challenges.

Our objectives were to compare incretin concentrations and rates of glucose production and gluconeogenesis in youth with type 2 diabetes before and after short-term metformin therapy compared with peers with normal glucose tolerance (NGT)